Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
RNA interference (RNAi)
Biotech
Roche inks $1.16B Rona deal to enter emerging obesity race
Roche has committed $100 million in upfront and near-term payments to join Alnylam, Arrowhead, GSK and Novo Nordisk in an emerging obesity niche.
Nick Paul Taylor
Oct 13, 2026 7:45am
Don't count out Alnylam's next-gen silencer in ATTR-CM: analysts
Sep 1, 2026 1:55pm
City lays foundation for RNAi renaissance with nearly $100M
Jun 8, 2026 4:00pm
Roche continues RNA return with $1.7B deal for Sanegene drug
Feb 2, 2026 8:35am
Irish biotech launches with $21M to shuttle RNAi meds to brain
Oct 1, 2025 10:34am
Corsera launches with $50M for predictive AI tool, RNAi asset
Sep 2, 2025 6:30am
